<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36868923</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1806-4841</ISSN><JournalIssue CitedMedium="Internet"><Volume>98</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Season>May-Jun</Season></PubDate></JournalIssue><Title>Anais brasileiros de dermatologia</Title><ISOAbbreviation>An Bras Dermatol</ISOAbbreviation></Journal><ArticleTitle>Cutaneous lupus erythematosus: a review of etiopathogenic, clinical, diagnostic and therapeutic aspects.</ArticleTitle><Pagination><StartPage>355</StartPage><EndPage>372</EndPage><MedlinePgn>355-372</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.abd.2022.09.005</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0365-0596(23)00024-7</ELocationID><Abstract><AbstractText>Cutaneous lupus erythematosus is an autoimmune disease of varied clinical expression, which may present as an exclusively cutaneous disease or be one of the multiple manifestations of systemic lupus erythematosus. Its classification includes acute, subacute, intermittent, chronic and bullous subtypes, which are usually identified based on clinical features and histopathological and laboratory findings. Other non-specific cutaneous manifestations may be associated with systemic lupus erythematosus and are usually related to disease activity. Environmental, genetic and immunological factors play a role in the pathogenesis of skin lesions in lupus erythematosus. Recently, considerable progress has been made in elucidating the mechanisms involved in their development, which allows for foreseeing future targets for more effective treatments. This review proposes to discuss the main etiopathogenic, clinical, diagnostic and therapeutic aspects of cutaneous lupus erythematosus, aiming to update internists and specialists from different areas.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Sociedade Brasileira de Dermatologia. Published by Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vale</LastName><ForeName>Everton Carlos Siviero do</ForeName><Initials>ECSD</Initials><AffiliationInfo><Affiliation>Dermatology Service, Hospital das Cl&#xed;nicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil. Electronic address: everton.siviero@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia</LastName><ForeName>Lucas Campos</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Dermatology Service, Hospital das Cl&#xed;nicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil; Department of Internal Medicine, Faculty of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>An Bras Dermatol</MedlineTA><NlmUniqueID>0067662</NlmUniqueID><ISSNLinking>0365-0596</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008179" MajorTopicYN="Y">Lupus Erythematosus, Discoid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008178" MajorTopicYN="Y">Lupus Erythematosus, Cutaneous</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001327" MajorTopicYN="Y">Autoimmune Diseases</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012867" MajorTopicYN="N">Skin</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Autoimmune diseases</Keyword><Keyword MajorTopicYN="N">Lupus erythematosus, cutaneous</Keyword><Keyword MajorTopicYN="N">Lupus erythematosus, discoid</Keyword><Keyword MajorTopicYN="N">Lupus erythematosus, systemic</Keyword><Keyword MajorTopicYN="N">Panniculitis, lupus erythematosus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>3</Day><Hour>22</Hour><Minute>6</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36868923</ArticleId><ArticleId IdType="pmc">PMC10173173</ArticleId><ArticleId IdType="doi">10.1016/j.abd.2022.09.005</ArticleId><ArticleId IdType="pii">S0365-0596(23)00024-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wenzel J. Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies. Nat Rev Rheumatol. 2019;15:519&#x2013;532.</Citation><ArticleIdList><ArticleId IdType="pubmed">31399711</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper E.E., Pisano C.E., Shapiro S.C. Cutaneous manifestations of &#x201c;lupus&#x201d;: systemic lupus erythematosus and beyond. Int J Rheumatol. 2021;2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8154312</ArticleId><ArticleId IdType="pubmed">34113383</ArticleId></ArticleIdList></Reference><Reference><Citation>Filotico R., Mastrandrea V. Cutaneous lupus erythematosus: clinico-pathologic correlation. G Ital Dermatol Venereol. 2018;153:216&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pubmed">29368845</ArticleId></ArticleIdList></Reference><Reference><Citation>Petty A.J., Floyd L., Henderson C., Nicholas M.W. Cutaneous lupus erythematosus: progress and challenges. Curr Allergy Asthma Rep. 2020;20:12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7548961</ArticleId><ArticleId IdType="pubmed">32248318</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarrett P., Werth V.P. A review of cutaneous lupus erythematosus: improving outcomes with a multidisciplinary approach. J Multidiscip Healthc. 2019;12:419&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6549666</ArticleId><ArticleId IdType="pubmed">31213824</ArticleId></ArticleIdList></Reference><Reference><Citation>Blake S.C., Daniel B.S. Cutaneous lupus erythematosus: a review of the literature. Int J Womens Dermatol. 2019;5:320&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6938925</ArticleId><ArticleId IdType="pubmed">31909151</ArticleId></ArticleIdList></Reference><Reference><Citation>Batalla A., Garc&#xed;a-Doval I., Pe&#xf3;n G., de la Torre C. A quality-of-life study of cutaneous lupus erythematosus. Actas Dermosifiliogr. 2013;104:800&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pubmed">23787361</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M., Orbai A.M., Alarc&#xf3;n G.S., Gordon C., Merrill J.T., Fortin P.R., et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64:2677&#x2013;2686.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409311</ArticleId><ArticleId IdType="pubmed">22553077</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M., Costenbader K., Daikh D., Brinks R., Mosca M., Ramsey-Goldman R., et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2019;71:1400&#x2013;1412.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6827566</ArticleId><ArticleId IdType="pubmed">31385462</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan B.C.H., Tang I., Bonin J., Koelmeyer R., Hoi A. The performance of different classification criteria for systemic lupus erythematosus in a real-world rheumatology department. Rheumatology (Oxford). 2022;00:1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9629341</ArticleId><ArticleId IdType="pubmed">35348630</ArticleId></ArticleIdList></Reference><Reference><Citation>Ribero S., Sciascia S., Borradori L., Lipsker D. The cutaneous spectrum of lupus erythematosus. Clin Rev Allergy Immunol. 2017;53:291&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">28752372</ArticleId></ArticleIdList></Reference><Reference><Citation>Hejazi E.Z., Werth V.P. Cutaneous lupus erythematosus: an update on pathogenesis, diagnosis and treatment. Am J Clin Dermatol. 2016;17:135&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">26872954</ArticleId></ArticleIdList></Reference><Reference><Citation>Elman S.A., Joyce C., Braudis K., Chong B.F., Fernandez A.P., Furukawa F., et al. Creation and validation of classification criteria for discoid lupus erythematosus. JAMA Dermatol. 2020;156:901&#x2013;906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7301299</ArticleId><ArticleId IdType="pubmed">32584927</ArticleId></ArticleIdList></Reference><Reference><Citation>Little A.J., Vesely M.D. Cutaneous lupus erythematosus: current and future pathogenesis-directed therapies. Yale J Biol Med. 2020;93:81&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7087060</ArticleId><ArticleId IdType="pubmed">32226339</ArticleId></ArticleIdList></Reference><Reference><Citation>Oke V., Wahren-Herlenius M. Cutaneous lupus erythematosus: clinical aspects and molecular pathogenesis. J Intern Med. 2013;273:544&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pubmed">23464352</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q., Wu H., Zhou S., Zhao M., Lu Q. An update on the pathogenesis of skin damage in lupus. Curr Rheumatol Rep. 2020;22:16.</Citation><ArticleIdList><ArticleId IdType="pubmed">32399815</ArticleId></ArticleIdList></Reference><Reference><Citation>Garelli C.J., Refat M.A., Nanaware P.P., Ramirez-Ortiz Z.G., Rashighi M., Richmond J.M. Current insights in cutaneous lupus erythematosus immunopathogenesis. Front Immunol. 2020;11:1353.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7343764</ArticleId><ArticleId IdType="pubmed">32714331</ArticleId></ArticleIdList></Reference><Reference><Citation>Hile G.A., Kahlenberg J.M. Immunopathogenesis of skin injury in systemic lupus erythematosus. Curr Opin Rheumatol. 2021;33:173&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8208233</ArticleId><ArticleId IdType="pubmed">33315653</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q., Wu H., Liao W., Zhao M., Chan V., Li L., et al. A comprehensive review of immune-mediated dermatopathology in systemic lupus erythematosus. J Autoimmun. 2018;93:1&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">30017673</ArticleId></ArticleIdList></Reference><Reference><Citation>Kudsi M., Nahas L.D., Alsawah R., Hamsho A., Omar A. The prevalence of oral mucosal lesions and related factors in systemic lupus erythematosus patients. Arthritis Res Ther. 2021;23:229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8414847</ArticleId><ArticleId IdType="pubmed">34479636</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts E.J., Melchionda V., Saldanha G., Shaffu S., Royle J., Harman K.E. Toxic epidermal necrolysis-like lupus. Clin Exp Dermatol. 2021;46:1299&#x2013;1303.</Citation><ArticleIdList><ArticleId IdType="pubmed">33760256</ArticleId></ArticleIdList></Reference><Reference><Citation>Nico M.M., Vilela M.A., Rivitti E.A., Louren&#xe7;o S.V. Oral lesions in lupus erythematosus: correlation with cutaneous lesions. Eur J Dermatol. 2008;18:376&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pubmed">18573706</ArticleId></ArticleIdList></Reference><Reference><Citation>Borucki R., Werth V.P. Cutaneous lupus erythematosus induced by drugs - novel insights. Expert Rev Clin Pharmacol. 2020;13:35&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">31774327</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y., Sawalha A.H. Drug-induced lupus erythematosus: an update on drugs and mechanisms. Curr Opin Rheumatol. 2018;30:490&#x2013;497.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7299070</ArticleId><ArticleId IdType="pubmed">29870500</ArticleId></ArticleIdList></Reference><Reference><Citation>Michaelis T.C., Sontheimer R.D., Lowe G.C. An update in drug-induced subacute cutaneous lupus erythematosus. Dermatol Online J. 2017;23 13030/qt55x42822.</Citation><ArticleIdList><ArticleId IdType="pubmed">28329511</ArticleId></ArticleIdList></Reference><Reference><Citation>Bataille P., Chasset F., Monfort J.B., De Risi-Pugliese T., Soria A., Franc&#xe8;s C., et al. Cutaneous drug-induced lupus erythematosus: clinical and immunological characteristics and update on new associated drugs. Ann Dermatol Venereol. 2021;148:211&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">34711400</ArticleId></ArticleIdList></Reference><Reference><Citation>Szcz&#x119;ch J., Samotij D., Werth V.P., Reich A. Trigger factors of cutaneous lupus erythematosus: a review of current literature. Lupus. 2017;26:791&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pubmed">28173739</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiga E., Caproni M., Bonciani D., Bonciolini V., Fabbri P. The last word on the so-called&#x2019; Rowell&#x2019;s syndrome&#x2019;? Lupus. 2012;21:577&#x2013;585.</Citation><ArticleIdList><ArticleId IdType="pubmed">22170759</ArticleId></ArticleIdList></Reference><Reference><Citation>Derdulska J.M., Rudnicka L., Szykut-Badaczewska A., Mehrholz D., Nowicki R.J., Bara&#x144;ska-Rybak W., et al. Neonatal lupus erythematosus - practical guidelines. J Perinat Med. 2021;49:529&#x2013;538.</Citation><ArticleIdList><ArticleId IdType="pubmed">33470961</ArticleId></ArticleIdList></Reference><Reference><Citation>Kus K.J.B., LaChance A.H., Vleugels R.A. Recognition and management of cutaneous connective tissue diseases. Med Clin North Am. 2021;105:757&#x2013;782.</Citation><ArticleIdList><ArticleId IdType="pubmed">34059249</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirali S., Mufti A., Lansang R.P., Sachdeva M., Yeung J. Development of chronic cutaneous lupus erythematosus during biologic therapy: a systematic review. J Am Acad Dermatol. 2021;84:835&#x2013;838.</Citation><ArticleIdList><ArticleId IdType="pubmed">33022308</ArticleId></ArticleIdList></Reference><Reference><Citation>Menzies S., O&#x2019;Shea F., Galvin S., Wynne B. Oral manifestations of lupus. Ir J Med Sci. 2018;187:91&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">28470356</ArticleId></ArticleIdList></Reference><Reference><Citation>Lospinoso D.J., Fernelius C., Edhegard K.D., Finger D.R., Arora N.S. Lupus erythematosus/lichen planus overlap syndrome: successful treatment with acitretin. Lupus. 2013;22:851&#x2013;854.</Citation><ArticleIdList><ArticleId IdType="pubmed">23761099</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitz S., Vatanchi M., Alapati U. Seven-year itch: a perplexing case of lichen planus-lupus erythematosus overlap syndrome. Dermatol Online J. 2018;24 13030/qt40g268t4.</Citation><ArticleIdList><ArticleId IdType="pubmed">30677835</ArticleId></ArticleIdList></Reference><Reference><Citation>Canu D., Viallard J.F., Lazaro E., Doutre M.S. Association of chilblain lupus and anti-Ro/SSA and anti-La/SSB antibodies: a study of 30 cases. Int J Dermatol. 2021;60:e509&#x2013;e511.</Citation><ArticleIdList><ArticleId IdType="pubmed">34021592</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubey S., Joshi N., Stevenson O., Gordon C., Reynolds J.A. Chilblains in immune mediated inflammatory diseases: a review. Rheumatology (Oxford). 2022;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9383735</ArticleId><ArticleId IdType="pubmed">35412601</ArticleId></ArticleIdList></Reference><Reference><Citation>Cozzani E., Herzum A., Burlando M., Parodi A. Comedonal variant of chronic cutaneous lupus erythematosus causing mutilation of the earlobe. JAAD Case Rep. 2020;6:843&#x2013;844.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7452277</ArticleId><ArticleId IdType="pubmed">32875034</ArticleId></ArticleIdList></Reference><Reference><Citation>Chess&#xe9; C., Fern&#xe1;ndez-Tapia M.J., Borzotta F. Comedonic lupus: an unusual presentation of cutaneous lupus. Actas Dermosifiliogr (Engl Ed). 2021;112:370&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pubmed">33130011</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia L.C., Morato I.B., Melo R.F.Q., Vale E.C.S. Comedogenic lupus: a rare variant of chronic cutaneous lupus erythematosus - case series. An Bras Dermatol. 2023;S0365-0596(22):00282-3. Online ahead of print.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9984717</ArticleId><ArticleId IdType="pubmed">36707354</ArticleId></ArticleIdList></Reference><Reference><Citation>Patsinakidis N., Kautz O., Gibbs B.F., Raap U. Lupus erythematosus tumidus: clinical perspectives. Clin Cosmet Investig Dermatol. 2019;12:707&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6778445</ArticleId><ArticleId IdType="pubmed">31632119</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitt V., Meuth A.M., Amler S., Kuehn E., Haust M., Messer G., et al. Lupus erythematosus tumidus is a separate subtype of cutaneous lupus erythematosus. Br J Dermatol. 2010;162:64&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">19712116</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoki V., Vale E.C.S. In: Dermatoses bolhosas autoimunes. Aoki V., Maruta C.W., Santi C.G., editors. Atheneu; S&#xe3;o Paulo: 2016. L&#xfa;pus eritematoso sist&#xea;mico bolhoso; pp. 119&#x2013;128.</Citation></Reference><Reference><Citation>de Risi-Pugliese T., Cohen-Aubart F., Haroche J., Moguelet P., Grootenboer-Mignot S., Mathian A., et al. Clinical, histological, immunological presentations and outcomes of bullous systemic lupus erythematosus: 10 new cases and a literature review of 118 cases. Semin Arthritis Rheum. 2018;48:83&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">29191376</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutnin S., Chanprapaph K. Vesiculobullous diseases in relation to lupus erythematosus. Clin Cosmet Investig Dermatol. 2019;12:653&#x2013;667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6732903</ArticleId><ArticleId IdType="pubmed">31564947</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenormand C., Lipsker D. Lupus erythematosus: significance of dermatologic findings. Ann Dermatol Venereol. 2021;148:6&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">33483145</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampaio A.L., Bressan A.L., Vasconcelos B.N., Gripp A.C. Skin manifestations associated with systemic diseases - Part I. An Bras Dermatol. 2021;96:655&#x2013;671.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8790165</ArticleId><ArticleId IdType="pubmed">34544638</ArticleId></ArticleIdList></Reference><Reference><Citation>Bitar C., Menge T.D., Chan M.P. Cutaneous manifestations of lupus erythematosus: a practical clinicopathological review for pathologists. Histopathology. 2022;80:233&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">34197657</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn A., Landmann A. The classification and diagnosis of cutaneous lupus erythematosus. J Autoimmun. 2014;48-49:14&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">24486120</ArticleId></ArticleIdList></Reference><Reference><Citation>Baltaci M., Fritsch P. Histologic features of cutaneous lupus erythematosus. Autoimmun Rev. 2009;8:467&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pubmed">19162243</ArticleId></ArticleIdList></Reference><Reference><Citation>Reimann J.D.R., Moynihan S.P., Horn T.D. Assessment of clinical and laboratory use of the cutaneous direct immunofluorescence assay. JAMA Dermatol. 2021;157:1343&#x2013;1348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8495595</ArticleId><ArticleId IdType="pubmed">34613346</ArticleId></ArticleIdList></Reference><Reference><Citation>Didier K., Bolko L., Giusti D., Toquet S., Robbins A., Antonicelli F., et al. Autoantibodies associated with connective tissue diseases: what meaning for clinicians? Front Immunol. 2018;9:541.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5879136</ArticleId><ArticleId IdType="pubmed">29632529</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou W., Wu H., Zhao M., Lu Q. New insights into the progression from cutaneous lupus to systemic lupus erythematosus. Expert Rev Clin Immunol. 2020;16:829&#x2013;837.</Citation><ArticleIdList><ArticleId IdType="pubmed">32746644</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakka S., Krain R.L., Concha J.S.S., Chong B.F., Merola J.F., Werth V.P. The CLASI, a validated tool for the evaluation of skin disease in lupus erythematosus: a narrative review. Ann Transl Med. 2021;9:431.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8033342</ArticleId><ArticleId IdType="pubmed">33842652</ArticleId></ArticleIdList></Reference><Reference><Citation>Mack E., Exton L.S., Mohd-Mustapa M.F., McCourt C., O&#x2019;Kane D. Use of the Cutaneous Lupus Disease Area and Severity Index as an outcome measure in clinical trials: a descriptive study. Clin Exp Dermatol. 2021;46:147&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pubmed">32790078</ArticleId></ArticleIdList></Reference><Reference><Citation>Nutan F., Ortega-Loayza A.G. Cutaneous lupus: a brief review of old and new medical therapeutic options. J Investig Dermatol Symp Proc. 2017;18:S64&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">28941497</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi H., Gudjonsson J.E., Kahlenberg J.M. Treatment of cutaneous lupus erythematosus: current approaches and future strategies. Curr Opin Rheumatol. 2020;32:208&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7357847</ArticleId><ArticleId IdType="pubmed">32141953</ArticleId></ArticleIdList></Reference><Reference><Citation>Fairley J.L., Oon S., Saracino A.M., Nikpour M. Management of cutaneous manifestations of lupus erythematosus: a systematic review. Semin Arthritis Rheum. 2020;50:95&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">31526594</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan D., Borucki R., Sontheimer R.D., Werth V.P. Candidate drug replacements for quinacrine in cutaneous lupus erythematosus. Lupus Sci Med. 2020;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7577055</ArticleId><ArticleId IdType="pubmed">33082164</ArticleId></ArticleIdList></Reference><Reference><Citation>Hannon C.W., McCourt C., Lima H.C., Chen S., Bennett C. Interventions for cutaneous disease in systemic lupus erythematosus. Cochrane Database Syst Rev. 2021;3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8092459</ArticleId><ArticleId IdType="pubmed">33687069</ArticleId></ArticleIdList></Reference><Reference><Citation>Chasset F., Franc&#xe8;s C. Current concepts and future approaches in the treatment of cutaneous lupus erythematosus: a comprehensive review. Drugs. 2019;79:1199&#x2013;1215.</Citation><ArticleIdList><ArticleId IdType="pubmed">31228033</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn A., Aberer E., Bata-Cs&#xf6;rg&#x151; Z., Caproni M., Dreher A., Frances C., et al. S2k guideline for treatment of cutaneous lupus erythematosus &#x2013; guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV) J Eur Acad Dermatol Venereol. 2017;31:389&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">27859683</ArticleId></ArticleIdList></Reference><Reference><Citation>Joseph A.K., Abbas L.F., Chong B.F. Treatments for disease damage in cutaneous lupus erythematosus: a narrative review. Dermatol Ther. 2021;34</Citation><ArticleIdList><ArticleId IdType="pubmed">34151487</ArticleId></ArticleIdList></Reference><Reference><Citation>de Sire A. Which interventions are effective for cutaneous disease in systemic lupus erythematosus? A Cochrane Review summary with commentary. Int J Rheum Dis. 2021;24:1540&#x2013;1542.</Citation><ArticleIdList><ArticleId IdType="pubmed">34533894</ArticleId></ArticleIdList></Reference><Reference><Citation>Chasset F., Bouaziz J.D., Costedoat-Chalumeau N., Franc&#xe8;s C., Arnaud L. Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis. Br J Dermatol. 2017;177:188&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">28112801</ArticleId></ArticleIdList></Reference><Reference><Citation>Reis Neto E.T., Kakehasi A.M., Pinheiro M.M., Ferreira G.A., Marques C.D.L., Mota L.M.H., et al. Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases. Adv Rheumatol. 2020;60:32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7282202</ArticleId><ArticleId IdType="pubmed">32517786</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A., Kostopoulou M., Alunno A., Aringer M., Bajema I., Boletis J.N., et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78:736&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pubmed">30926722</ArticleId></ArticleIdList></Reference><Reference><Citation>Moura Filho J.P., Peixoto R.L., Martins L.G., Melo S.D., Carvalho L.L., Pereira A.K., et al. Lupus erythematosus: considerations about clinical, cutaneous and therapeutic aspects. An Bras Dermatol. 2014;89:118&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3938362</ArticleId><ArticleId IdType="pubmed">24626656</ArticleId></ArticleIdList></Reference><Reference><Citation>Klebes M., Wutte N., Aberer E. Dapsone as second-line treatment for cutaneous lupus erythematosus? A retrospective analysis of 34 patients and a review of the literature. Dermatology. 2016;232:91&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">26606129</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuki E.F.N., Silva C.A., Aikawa N.E., Romiti R., Heise C.O., Bonfa E., et al. Thalidomide and lenalidomide for refractory systemic/cutaneous lupus erythematosus treatment: a narrative review of literature for clinical practice. J Clin Rheumatol. 2021;27:248&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">31693649</ArticleId></ArticleIdList></Reference><Reference><Citation>Chasset F., Tounsi T., Cesbron E., Barbaud A., Franc&#xe8;s C., Arnaud L. Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: a systematic review and meta-analysis. J Am Acad Dermatol. 2018;78:342&#x2013;350.</Citation><ArticleIdList><ArticleId IdType="pubmed">28989111</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>